SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
Q2 2026 vs. Q1 2026
How the institutions holding SAB Biotherapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 6 | 8 | +2 |
| Shares | 811.8K | 837.7K | +26.0K (+3.2%) |
| Value | $21.1K | $10.5K | −$10.6K (−50.3%) |
New holders (2)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Toronto Dominion Bank | 300 | $4 | 0.00% |
| Virtu Financial LLC | 21,223 | $0 | 0.00% |
Sold out (0)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
None.